MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
The Sales Director, HDV Business Unit will lead a highly specialized field team of Regional Account Managers (RAMs) tasked with preparing the U.S. market for the anticipated launch of Brelovitug for Hepatitis Delta Virus (HDV), pending regulatory approval. This role is responsible for advancing disease awareness, supporting account readiness, and helping to establish the foundation for appropriate patient identification and management in a market with profound unmet need.
HDV represents the most severe form of viral hepatitis, requiring Hepatitis B co-infection for replication and spread. Despite an estimated U.S. prevalence of ~40,000 patients and ~15,000 who are diagnosed, insured, and under care, there are currently no approved therapies in the U.S., underscoring the urgency and importance of this role.
This leader must excel at operating in ambiguity—defining strategy, building structure, and driving execution in a market that is still being shaped in real time.
JOB FUNCTIONS/RESPONSIBILITIES
Strategic Leadership
- Build and lead the HDV team of 6 Regional Account Managers across key U.S. geographies
- Develop and execute a pre-launch market development strategy focused on HDV disease awareness and diagnosis expansion
- Identify and prioritize high-value accounts within key HDV geographies
- Translate evolving epidemiology, market insights, and competitive dynamics into actionable, compliant field strategies
- Create clarity from ambiguity by setting direction, establishing priorities, and adapting strategy as new information emerges
Market Development & Disease Education
- Drive awareness of HDV as a severe, underdiagnosed condition requiring urgent intervention
- Expand understanding of the relationship between HDV and Hepatitis B (HBsAg dependency)
- Partner with KOLs and key institutions to support HDV screening, diagnosis, and referral pathways
- Support initiatives to improve patient identification within the estimated ~40,000 patients under care
Account Engagement & Activation
- Ensure strategic engagement across key stakeholders and health systems
- Establish account plans focused on screening protocols, care pathways, and disease management readiness
- Collaborate cross-functionally with Medical Affairs, Market Access, and Marketing to ensure aligned execution
- Support accounts in enhancing (or operationalizing) HDV identification and management in the absence of established standards
Team Leadership & Development
- Recruit, develop, and coach a high-impact team of RAMs
- Set clear expectations aligned with pre-launch, non-promotional objectives
- Foster a culture of accountability, agility, and mission-driven execution
- Coach the team to operate effectively without fixed playbooks—encouraging problem-solving, adaptability, and proactive compliant decision-making
- Lead through influence in a complex, cross-functional environment
Cross-Functional Collaboration
- Serve as the field leadership voice in launch planning
- Partner closely with:
- Medical Affairs on scientific exchange and KOL engagement (as appropriate and compliant)
- Market Access on payer readiness and coverage considerations
- Commercial leadership on launch readiness and execution
- Align stakeholders around evolving strategies, even when data, timelines, or market conditions are still emerging
QUALIFICATIONS
Education/Experience:
- Bachelor’s degree required; MBA or advanced degree preferred
- 7+ years of pharmaceutical/biotech experience, including field leadership
- Proven success leading account-based or specialty field teams through ambiguity
- Experience in rare disease, hepatology, infectious disease, or specialty launches
- Demonstrated ability to build strategy in pre-launch environments
- Strong understanding of U.S. healthcare systems, IDNs, and academic centers
- Experience with Hepatitis B, liver disease, or transplant networks preferred
- Launch experience in a market with low awareness/high unmet need
- Strong KOL engagement and scientific fluence
- Thrives in a fast-paced, dynamic, and collaborative environment
- Able to travel frequently, up to 70% overnight travel and has a valid drivers’ license
KEY COMPETENCIES
- Strategic thinker with strong execution discipline
- Comfort leading through ambiguity—able to make decisions with incomplete information and adjust rapidly
- Ability to build structure and momentum from the ground up
- Exceptional leadership and team development skills
- High emotional intelligence and stakeholder influence
- Mission-driven mindset aligned to addressing critical unmet need
- Ability to understand and effectively communicate scientific information within role and scope
- Foster a culture of innovation, accountability, and entrepreneurial thinking
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Skills Required
- Bachelor's degree required; MBA or advanced degree preferred
- 7+ years of pharmaceutical/biotech experience, including field leadership
- Proven success leading account-based or specialty field teams through ambiguity
- Experience in rare disease, hepatology, infectious disease, or specialty launches
- Strong understanding of U.S. healthcare systems, IDNs, and academic centers
- Strong KOL engagement and scientific fluence
- Able to travel frequently, up to 70% overnight
Mirum Pharmaceuticals Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Mirum Pharmaceuticals and has not been reviewed or approved by Mirum Pharmaceuticals.
-
Equity Value & Accessibility — Equity grants to new hires and an employee stock purchase plan make ownership more accessible and can boost total rewards when performance is strong. Public disclosures highlight frequent option/RSU inducements.
-
Healthcare Strength — Comprehensive medical, dental, and vision coverage is employer-paid for employees, with added life, disability, and EAP support. This combination reduces financial burden and enhances overall wellbeing.
-
Leave & Time Off Breadth — A broad time-off program includes multiple paid company holidays, a year-end shutdown, accrued vacation, and paid parental leave. This breadth provides additional rest periods beyond standard vacation.
Mirum Pharmaceuticals Insights
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
